Date: 2017-09-06
Type of
information: Initiation of development program
phase: 1
Announcement: initiation of development program
Company: Synairgen (UK)
Product: PXS-5382A
Action
mechanism:
- enzyme inhibitor/lysyl oxidase type 2 enzyme (LOXL2) inhibitor. LOXL2 is a pro-fibrotic enzyme believed to play a significant role in the collagen cross-linking formation process in fibrotic diseases such as NASH, cardiac fibrosis, kidney fibrosis and IPF. PXS-5382A is a potent and selective inhibitor of LOXL2 and has consistently been shown to significantly reduce and inhibit cross-linking formation in in vitro and in vivo models of lung, liver and cardiac fibrosis. These findings have been the subject of presentations at numerous international scientific conferences and more data will be presented at similar upcoming events as the Phase I trial proceeds.
- PXS-5382A is being developed in partnership with Pharmaxis to target the fatal lung disease idiopathic pulmonary fibrosis and other fibrotic conditions including non-alcoholic steatohepatitis (NASH), kidney fibrosis and heart fibrosis. It comes from the same Pharmaxis chemistry platform as the SSAO inhibitor that was recently acquired by Boehringer Ingelheim.
Disease: idiopathic pulmonary fibrosis (IPF) and other fibrotic conditions including non-alcoholic steatohepatitis (NASH), kidney fibrosis and heart fibrosis
Therapeutic
area: Lung diseases - Respiratory diseases - Rare diseases - Fibrotic diseases
Country:
Trial
details:
Latest
news:
- • On September 6, 2017, Synairgen announced that, following the successful completion of preclinical pharmacology and toxicology studies, a compound from its anti-fibrotic Lysyl Oxidase type 2 (LOXL2) inhibitor programme, PXS-5382A, is being prepared to commence Phase I clinical development.
Synairgen will progress PXS-5382A through the Phase I trial, the results of which are expected mid-2018. Thereafter Synairgen and Pharmaxis plan to out-license PXS-5382A to a suitable partner to fully realise the commercial value of this compound given the potential size and number of indications it could address.
Is
general: Yes
